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Abstract
Background: This analysis aims to evaluate health-related quality of life (HrQoL) (primary outcome for this analysis),
nausea and vomiting, and pain in patients with inoperable malignant bowel obstruction (IMBO) due to cancer or its
treatments randomised to standardised therapies plus octreotide or placebo over a maximum of 72 h in a double-
blind clinical trial.
Methods: Adults with IMBO and vomiting recruited through 12 services spanning inpatient, consultative and
community settings in Australia were randomised to subcutaneous octreotide infusion or saline. HrQoL was
measured at baseline and treatment cessation (EORTC QLQ-C15-PAL). Mean within-group paired differences
between baseline and post-treatment scores were analysed using Wilcoxon Signed Rank test and between group
differences estimated using linear mixed models, adjusted for baseline score, sex, age, time, and study arm.
Results: One hundred six of the 112 randomised participants were included in the analysis (n = 52 octreotide, n =
54 placebo); 6 participants were excluded due to major protocol violations. Mean baseline HrQoL scores were low
(octreotide 22.1, 95% CI 14.3, 29.9; placebo 31.5, 95% CI 22.3, 40.7). There was no statistically significant within-group
improvement in the mean HrQoL scores in the octreotide (p = 0.21) or placebo groups (p = 0.78), although both
groups reported reductions in mean nausea and vomiting (octreotide p < 0.01; placebo p = 0.02) and pain scores
(octreotide p < 0.01; placebo p = 0.03). Although no statistically significant difference in changes in HrQoL scores
between octreotide and placebo were seen, an adequately powered study is required to fully assess any differences
in HrQoL scores.
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Conclusion: The HrQoL of patients with IMBO and vomiting is poor. Further research to formally evaluate the
effects of standard therapies for IMBO is therefore warranted.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12608000211369 (date registered 18/04/
2008)
Keywords: Patient-reported outcome measures, Neoplasms, Intestinal obstruction, Terminal care, Palliative care,
Randomised controlled trials
Background
Bowel obstruction due to cancer or its treatments (malig-
nant bowel obstruction (MBO)) is prevalent in the ad-
vanced stages of illness [1, 2]. For many, this is an
inoperable problem due to multi-level obstruction, likely
intolerance of the catabolic insult of surgery due to poor
health, peritoneal carcinomatosis, complications from pre-
vious intra-abdominal surgeries or a combination of these
contraindications. In this setting, good symptom control,
particularly for nausea and vomiting, becomes the over-
arching therapeutic goal [3]. For most people with inoper-
able malignant bowel obstruction (IMBO), prognosis is
very poor [3]. Interventions that predictably and quickly
reduce the frequency and volume of vomiting are re-
quired. However, to date, there are no registered medica-
tions for the symptomatic treatment of IMBO [4].
An adequately powered randomized, double-blind,
placebo-controlled trial evaluating the net effect of add-
ing octreotide (a somatostatin analogue) or placebo to
standardised therapies (ranitidine, dexamethasone, low
dose subcutaneous hydration) in people with IMBO [4]
failed to demonstrate a statistically significant or clinic-
ally important difference in the number of patient-
reported days free of vomiting at 72 h. Joint consider-
ation of the primary, secondary and safety outcomes,
and patient net clinical benefit is recommended when
interpreting the findings of such well-designed clinical
trials [5]. Although there were no statistically significant
differences between groups for almost all of the second-
ary outcomes, participants receiving octreotide experi-
enced a reduction in the number of episodes of vomiting
compared with placebo (incidence rate ratio 0.40, 95%
CI 0.19–0.86, p-value = 0.02). At the same time, people
in the octreotide arm were twice as likely to be adminis-
tered hyoscine butylbromide each day compared with
placebo (p-value < 0.01), possibly due to more colicky
pain, greater pain severity or both [4]. Given these differ-
ences, octreotide may have distinctive effects on health-
related quality of life (HrQoL) domains and overall qual-
ity of life compared with placebo.
This paper reports the first analysis of HrQoL in a ran-
domized trial comparing octreotide with placebo. To
date, the previously published studies examining this
issue [6] in similar populations have been mixed [7–9].
Matulonis and colleagues [8] reported no statistically
significant differences among any HrQoL scores (mea-
sured using the EORTC QLQ-C30/ OV28) in people
with advanced cancer and inoperable, clinically or radio-
graphically diagnosed bowel obstruction treated with
octreotide up to 12months duration. In contrast, Shima
et al. [9] found that some aspects of HrQoL (measured
using a subjective self-administered questionnaire), such
as alleviation of nausea and vomiting and enjoyment of
recreational activities, did improve after 6 days of octreo-
tide therapy in patients with malignant bowel obstruc-
tion refractory to other medical treatment. Finally,
Hisanaga and colleagues [7] reported a statistically sig-
nificant improvement in overall HrQoL (measured using
a face scale, p < 0.001) in palliative patients with IMBO
treated with octreotide for 3 days but, of note, no im-
provement in pain. However, as all of these results were
derived from lower levels of evidence more prone to
bias, predominantly due to a lack of control group, the
findings should be interpreted cautiously [10]. Recently,
Obita et al. [11] conducted a systematic review assessing
the efficacy of somatostatin analogues for symptomatic
treatment of nausea and vomiting in people with ad-
vanced cancer and malignant bowel obstruction and
concluded whilst there was low level evidence of benefit,
higher quality studies with a low risk of bias did not
demonstrate benefit, consistent with the results from
this study.
More generally, there is very little published data on
the HrQoL of people with IMBO using validated instru-
ments [12–14]. Observational data (n = 35) reported by
Selby and colleagues indicate patients presenting with
malignant bowel obstruction from metastatic intra-
abdominal disease have very poor HrQoL and a high
symptom burden, as measured with the Rotterdam
Symptom Checklist (RSCL) and Edmonton Symptom
Assessment Scale (ESAS) respectively [12]. Detailed ana-
lysis of the HrQoL data collected during the octreotide
study conducted by Currow and colleagues [4] using the
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC) QLQ-
C15-PAL helps address this knowledge gap.
The primary aim of this current analysis of prospect-
ively collected data from the octreotide randomised
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controlled trial (RCT) was to evaluate whether there is a
difference in overall HrQoL between participants treated
with octreotide and placebo. The secondary aims were
to compare the pain and nausea and vomiting dimen-
sions of HrQoL in the treatment arms and evaluate the
HrQoL of people with IMBO. A preliminary analysis of
these data has been previously presented at the 15th
World Congress of the European Association for Pallia-
tive Care, 18–20 May 2017, Madrid, Spain [15].
Methods
Setting
The Palliative Care Clinical Studies Collaborative (PaCCSC)
is a national research network established in 2006 with
funding from the Australian Government, conducting ro-
bust, multi-site, RCTs investigating the effectiveness and
cost-effectiveness of symptom treatments in palliative care
[16]. This PaCCSC RCT was conducted between August
2008 and May 2012 and was approved by the ethics com-
mittees of 12 participating sites spanning all clinical settings
(inpatient, consultative, community) across Australia. Par-
ticipants provided written informed consent. The study was
registered in the Australian New Zealand Clinical Trials
Registry (ACTRN12608000211369, <https://www.anzctr.
org.au/Trial/Registration/TrialReview.aspx?id=82724>). Full
details of the trial are reported elsewhere [4] and briefly
summarised below.
Trial design
Adults with IMBO (diagnosed on clinical grounds by
two independent medical practitioners) and vomiting for
whom further anti-cancer therapies were not immedi-
ately appropriate were randomised to a subcutaneous in-
fusion of octreotide (600 mg/24 h) or normal saline
(placebo) for a maximum of 72 h. Trained palliative care
research nurses obtained consent and enrolled potential
participants identified by clinicians (emergency, surgical,
general medicine, and oncology departments and pallia-
tive care services) in participating institutions and their
associated community teams. The eligibility criteria are
summarized in Table 1.
Randomised treatment was combined with standar-
dised therapies which included regular parenteral dexa-
methasone (8 mg/day), ranitidine (200 mg/24 h), and
hydration (10–20mL/kg/day unless overtly dehydrated
at study entry) [4]. Standardised “as-needed” therapies
were available for managing expected symptoms during
the study period including; hyoscine butylbromide for
colicky abdominal pain, haloperidol for nausea, and par-
enteral opioids for pain. Participants were randomized in
blocks of four by site in a 1:1 ratio and randomization
schedules were developed for each site using random
number tables, generated centrally [4]. Site pharmacists,
uninvolved in the participants’ care, opened the
treatment schedules. Syringes were identical in colour
and volume. Participants, assessors and clinical staff
were blinded to treatment allocations. The primary out-
come was the number of patient-reported days free of
vomiting at 72 h. Secondary outcomes, also measured at
72 h, included the number of patient-reported episodes
of vomiting, episodes of vomiting per day, survival, level
of nausea (numerical rating scale), average pain score
(Brief Pain Inventory [BPI]) [17], functional status
(Australia-modified Karnofsky Performance Status
[AKPS]) [18], protocol-defined as-needed symptom con-
trol medications, patient-rated Global Impression of
Change (GIC) and HrQoL [4, 19].
Health-related quality of life (HrQoL)
Health-related quality of life was measured using the
EORTC QLQ-C15-PAL questionnaire which was admin-
istered at baseline and treatment cessation. The EORTC
QLQ-C15-PAL is a shortened version of the widely used
cancer-specific HrQoL measure, the EORTC QLQ-C30
[20], and was specifically developed for palliative care.
The EORTC QLQ-C15-PAL questionnaire consists of
14 items, each with four possible responses (not at all =
1, a little = 2, quite a bit = 3, and very much = 4), and an
overall HrQoL rating scale with seven categories ranging
from 0 (very poor) to 7 (excellent) [21]. The 14 items
are grouped into two functional scales (physical and
emotional), five single-item symptom scales (dyspnoea,
Table 1 Eligibility criteria [4]
Inclusion criteria Exclusion criteria
Age > 18 years Previous adverse reaction to
any of the study medications
Advanced cancer Australia-modified Karnofsky





is unlikely to change the bowel
obstruction.
Participated in a clinical study
of a new chemical entity
< 1 month before study entry
Presents with clinically confirmed
bowel obstruction with vomiting
that precipitates change in clinical
care or a hospital admission.
Calculated creatinine
clearance < 10 mL/minute
A partial or complete bowel
obstruction for which immediate
surgery is not indicated (confirmed




Able to complete assessments and




Able to give fully informed written
consent
Not currently on octreotide
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insomnia, appetite loss, constipation, nausea and vomit-
ing) and two multi-item symptom scales (pain and fa-
tigue). A scoring algorithm is used to convert the
response categories to a score (0–100) [22, 23]. Lower
scores on the functional scales indicate reduced levels of
functioning, whereas on the symptom scales, lower
scores indicate a reduced symptom burden. Note the
EORTC-QLQ-C15 questionnaire does not produce an
overall total score derived from all the items.
Analysis
Analysis of the HrQoL data was undertaken on an
intention-to-treat basis. Missing value patterns were ana-
lyzed using missing value analysis in SPSS® (SPSS, Inc.,
Chicago, IL) to evaluate whether there were systematic
differences between available and missing values. Follow-
ing Consolidated Standards of Reporting Trials (CON-
SORT) statement recommendations [24, 25], multiple
imputation was used to estimate participant-level miss-
ing HrQoL data with a fully conditional specification
model. All variables in the dataset were included in the
imputation model and 20 imputations were performed
[26, 27]. Statistical analyses were conducted using Statis-
tical Package for Social Sciences for Windows versions
23.0 and 24.0 (SPSS, Inc., Chicago, IL).
The pre-specified, null hypothesis for the primary
outcome in the HrQoL analysis was that there would
be no difference in overall HrQoL between treatment
arms. A difference of 10 points or more on the 100
point overall HrQoL scale (“How would you rate your
quality of life during the past week”) was considered
clinically meaningful based on earlier studies [28–31].
The alternative hypotheses for the secondary out-
comes, were that there would be a difference in the
nausea and vomiting and pain dimensions between
treatment arms, favouring octreotide. A difference of
13 points or more on the 100 point scale was consid-
ered clinically meaningful for the EORTC QLQ-C15-
PAL pain and nausea and vomiting dimensions based
on a recent study reporting minimal clinically import-
ant differences (MCID) estimated in patients with
bone metastases undergoing radiotherapy [30].
Descriptive statistics were calculated for clinico-
demographic variables and HrQoL scores. As the base-
line HrQoL scores were non-normally distributed (Kol-
mogorov-Smirnov test, p < 0.05), differences between
the two groups at baseline were assessed using the non-
parametric Mann Whitney U test [32]. Within-group
differences between baseline and post-treatment HrQoL
scores were analysed using the Wilcoxon Signed Rank
test [32]. Estimated marginal means (maximum likeli-
hood) and the adjusted mean difference between overall
HrQoL scores (primary outcome) and pain and nausea
and vomiting scores (secondary outcomes), with
associated 95% CI and p-values, were calculated using a
linear mixed effects model (LMM) with a random slope,
treatment group and time as fixed effects, and age, gen-
der and baseline scores as covariates [33]. A series of ex-
ploratory LMMs were conducted to confirm the fixed
and random effects and optimal covariance structure.
Akaike’s Information Criterion (AIC) was used to aid
identification of the best-fitting model [34]. The signifi-
cance level in secondary analyses was set at p < 0.05 with
two-sided significance tests.
Results
Overall, 112 participants were randomised, although six
participants were excluded from the analysis due to
major protocol violations of concomitant treatments
(Fig. 1). The intended cohort was recruited as planned.
Of the 106 participants included in the analysis, 52 were
randomised to octreotide and 54 to placebo. There were
no deaths in either group during the study.
In the octreotide group, the mean age was 62.9 (SD
13.6), and 90.4% of participants were female, whilst in
the placebo group, the mean age was slightly higher
(66.3 (SD 12.2)), and 70.4% of participants were female
(Table 2). For both groups, multi-level small bowel ob-
struction was the most common bowel obstruction, af-
fecting 34 participants (65.4%) in the octreotide group
and 34 (63.0%) in the placebo group. The median AKPS
score in both groups was 50 (requiring considerable as-
sistance). At baseline, overall HrQoL scores were low
(octreotide 22.1, 95% CI 14.3, 29.9; placebo 31.5, 95% CI
22.3, 40.7) whilst not statistically higher in the placebo
arm (p-value = 0.12). Given complete case and multiple
imputation descriptive analyses were similar only
complete case results are presented below. The multiple
imputation descriptive analyses are provided in Table
A1, Additional file 1.
Overall, 81 (76.4%) participants attempted the baseline
EORTC QLQ-C15-PAL questionnaire and 67 (63.2%)
participants attempted the questionnaire at treatment
cessation. Only 42 participants (39.6%) had no missing
responses for either questionnaire. Response rates for
the EORTC QLQ-C15-PAL functional, symptom and
overall HrQoL rating scales are summarised in Table
A2, Additional file 2. Total response rates for the indi-
vidual questionnaire items varied between 67.0% (n =
71) and 76.4% (n = 81) at baseline and 51.9% (n = 55)
and 63.2% (n = 67) post-treatment, and were similar be-
tween study arms. In both groups, there was a higher re-
sponse rate at baseline compared to treatment cessation.
Health-related quality of life scores
Baseline and post-treatment EORTC QLQ-C15-PAL
scores are presented in Table 3.
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There was no statistically significant within-group im-
provement in the mean HrQoL scores in the octreotide
(p = 0.21) or placebo groups (p = 0.78) (Table 3). Both
groups reported statistically significant and clinically
relevant reductions in mean nausea and vomiting
(octreotide p < 0.01; placebo p = 0.02) and pain scores
(octreotide p < 0.01; placebo p = 0.03). Post hoc analysis
of within-group changes in the remaining EORTC QLQ-
C15-PAL scores suggested scores generally improved
over the duration of the study: appetite loss and consti-
pation for both groups, sleep in the octreotide group
and dyspnoea in the placebo group.
Differences between groups were analysed using linear
mixed models, adjusting for baseline HrQoL scores, sex
and age (evidence in the literature suggests older respon-
dents and females have poorer health generally [35],
time and study arm. In the exploratory analyses, group
by time interaction was not statistically significant (most
post-treatment scores were collected on Day 3) and so
was removed from the final model. Table 4 summaries
the adjusted, estimated marginal mean post-treatment
scores and between-group differences.
The mean adjusted difference between the two treat-
ment arms for HrQOL was neither statistically signifi-
cant nor clinically important (0.5, 95% CI -10.4, 11.3).
Similar between group results were observed for the
nausea and vomiting (3.7, 95% CI -10.4, 17.7) and pain
scores (0.9, 95% CI -11.1, 12.8).
Fig. 1 CONSORT participant flow diagram [4]. Reprinted from Journal of Pain and Symptom Management, Volume 49, Issue 5, David C. Currow,
Stephen Quinn, Meera Agar et al., Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction, Pages 814–
821, Copyright (2015), with permission from Elsevier. https://doi.org/10.1016/j.jpainsymman.2014.09.013






Age in years, mean (SD) 62.9 (13.6) 66.3 (12.2)
Gender, female, n (%) 47 (90.4) 38 (70.4)
Performance status (AKPS),
median (IQR)
50 (40–60) 50 (40–60)
BPI pain score, median (IQR) 3 (1–5) 4 (1.25–5)
Nauseaa, median (IQR) 2 (1–2) 1(1–2)
Level of bowel obstruction
Gastric outlet/duodenal, n (%) 5 (9.6) 9 (16.7)
Small bowel/ multi-level, n (%) 34 (65.4) 34 (63.0)
Large bowel, n (%) 2 (3.9) 3 (5.6)
Indeterminate, n (%) 11 (21.2) 8 (14.8)
EORTC QLQ-C15-Pal overall
quality of life score, mean (SD)
22.1 (24.3) 31.5 (27.2)
AKPS Australia-modified Karnofsky Performance Status scale, scores range from
0 to 100 where a higher score indicates better performance in terms of work,
activity and self-care, BPI Brief Pain Inventory, scores range from 0 to 10 where
higher score represents more pain, EORTC QLQ-C15-Pal The European
Organization for Research and Treatment of Cancer quality of life palliative
care questionnaire, scores range from 0 to 100 and higher scores represent
better QOL, IQR Inter-quartile range, SD Standard deviation
anausea numerical rating scale ranges from 0 to 5, where a higher score
indicates more nausea
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Discussion
The findings from this pre-specified analysis of prospect-
ively collected HrQoL data from the PaCCSC octreotide
RCT suggest the overall quality of life of patients with
IMBO and vomiting is very poor. Health-related quality of
life, physical and emotional functioning and symptoms
measured using the EORTC QLQ-C15-PAL improved
over the study period for all participants. Participants re-
ported experiencing less nausea and vomiting, pain,
appetite loss and constipation post-treatment, irrespective
of treatment allocation. This may reflect the quality of
care delivered during the study, the natural history of
IMBO and the efficacy of the standardised therapies which
included ranitidine and dexamethasone. These therapies
provide promising opportunity for further exploration.
Although most symptom scale scores improved, there
was no statistically significant improvement in the over-
all quality of life suggesting other aspects outside of
Table 3 Baseline and post-treatment EORTC QLQ-C15-PAL scores
EORTC QLQ-C15-PAL
scalea
Octreotide (N = 52)
mean scores (95% CI)
Placebo (N = 54)
mean scores (95% CI)
Baseline Post-treatment p-value Baseline Post-treatment p-value


























































































Bolded numbers indicate statistically significant differences
HrQoL Health-related quality of life
amean unadjusted within-group paired differences between baseline and post-treatment scores were analysed using the Wilcoxon Signed Rank test. b higher
scores represent better outcomes; c higher scores represent greater symptom burden
Table 4 Adjusted estimated marginal mean EORTC QLQ-C15-PAL post-treatment scores
Scales
Mean (95% CI)
Octreotide (N = 52) Placebo (N = 54) Mean difference (95% CI) P-value
Overall HrQoLa 35.31 (21.68, 48.94) 34.86 (21.30, 48.41) 0.45 (−10.35, 11.26) 0.935
Physical functioninga 33.97 (21.30, 46.64) 31.01 (20.31, 41.69) 2.97 (−6.52, 12.46) 0.539
Emotional functioninga 60.30 (45.18, 75.42) 58.95 (46.22, 71.67) 1.36 (−10.40, 13.12) 0.821
Fatigueb 73.58 (60.28, 86.87) 72.88 (59.75, 86.00) 0.70 (−10.07, 11.46) 0.899
Nausea & vomitingb 51.45 (33.98, 68.91) 47.79 (32.39, 63.18) 3.66 (−10.35, 17.68) 0.608
Painb 56.38 (40.27, 72.49) 55.53 (42.61, 68.44) 0.85 (− 11.08, 12.79) 0.888
Dyspnoeab 31.67 (17.77, 45.54) 29.76 (17.00, 42.53) 1.89 (−9.69, 13.48) 0.748
Insomniab 41.00 (26.17, 55.84) 48.14 (34.14, 62.14) − 7.14 (− 20.88, 6.61) 0.308
Appetite lossb 52.10 (34.34, 69.87) 52.09 (34.90, 69.28) 0.16 (−14.23, 14.26) 0.998
Constipationb 49.45 (32.91, 65.99) 51.47 (37.22, 65.72) −2.02 (−16.22, 12.19) 0.780
HrQoL Health related quality of life
ahigher scores represent better outcomes
bhigher scores represent greater symptom burden
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those captured by the EORTC QLQ-C15-PAL influence
quality of life [36]. Overall, fatigue, appetite loss and
nausea and vomiting were the worst symptoms at base-
line, similar to the most predominant symptoms on the
ESAS scale in a prospective study of 35 patients admit-
ted to hospital with malignant bowel obstruction (appe-
tite loss, fatigue, drowsiness) [12].
Adding subcutaneous octreotide to standardized
therapies did not result in meaningful improvements
in HrQoL, pain or nausea and vomiting compared
with placebo in this setting and timeframe. The
HrQoL endpoints were secondary outcomes and the
study likely lacked adequate statistical power to assess
any differences in the impact of octreotide and pla-
cebo on HrQoL. An estimated sample size of 248
participants would be needed to detect a clinically
meaningful between-group difference of 10 points in
the overall HrQoL domain, with a power of 90% and
an alpha level of 0.05.
Strengths of this study include standardization of the
supportive care delivered in both arms using the best
available evidence [4]. The randomized, double-blind,
placebo-controlled trial, adequately powered for the pri-
mary outcome, was conducted across a range of clinical
practices reflecting the target population seen in hospice,
palliative care, and oncology settings, augmenting exter-
nal validity. The EORTC QLQ-C15-PAL is a brief, yet
comprehensive, validated instrument measuring HrQoL,
developed specifically for the palliative care setting [37].
The HrQoL data are derived from RCT evidence, min-
imizing potential sources of bias associated with lower
levels of evidence [6].
Similar to other studies involving a palliative care
population [21], there was a sizable proportion of
missing values in the data, although patterns of miss-
ing values between the study groups were similar.
Systematic differences between available and missing
baseline values could not be excluded as participants
with a higher performance status (as measured by the
AKPS) appeared more likely to complete baseline
questionnaires, indicating that physically unwell pa-
tients were less likely to respond. Post-treatment
questionnaire response rates were lower than baseline.
Typically, people with a life-limiting illness receiving
palliative care have poor health status which declines
over time and fatigue may be problematic in this frail
population, leading to a higher non-response rate
compared with other study populations. Despite these
caveats, multiple imputation, a robust statistical ap-
proach for dealing with missing data [26], was used
to minimise any potential bias due to missing values.
Conclusions
The HrQoL of patients with IMBO and vomiting is gen-
erally poor. Despite this, the findings from this study
suggest HrQoL can be improved over a relatively short
period of time with appropriate care. Formal evaluation
of the effects of ranitidine, dexamethasone, both or nei-
ther in this setting is warranted given the improvements
in nausea and vomiting, pain and HrQoL domains in the
study participants.
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